Compare ATCH & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATCH | LTRN |
|---|---|---|
| Founded | 2022 | 2013 |
| Country | United States | United States |
| Employees | 46 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.6M | 27.6M |
| IPO Year | 2024 | 2020 |
| Metric | ATCH | LTRN |
|---|---|---|
| Price | $0.18 | $1.11 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.00 | N/A |
| AVG Volume (30 Days) | ★ 3.8M | 233.7K |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.65 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $20,052,635.00 | N/A |
| Revenue This Year | $84.47 | N/A |
| Revenue Next Year | $39.32 | N/A |
| P/E Ratio | $9.14 | ★ N/A |
| Revenue Growth | ★ 84.70 | N/A |
| 52 Week Low | $0.17 | $1.08 |
| 52 Week High | $0.61 | $4.70 |
| Indicator | ATCH | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 44.26 | 20.81 |
| Support Level | $0.18 | $1.11 |
| Resistance Level | $0.22 | $1.96 |
| Average True Range (ATR) | 0.02 | 0.16 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 19.33 | 3.53 |
AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.